Abstract: A vehicle assembly includes a vehicle body and a driver seat. The vehicle body defines a driver compartment having a first door with a first window and a second door with a second window. The driver seat is disposed within the driver compartment. When the driver seat is in a position that accommodates an operator being in a 95th male height percentile, the operator within the driver seat can see out of (i) the first window at a first angle relative to a forward looking direction that is parallel with a longitudinal axis of the vehicle body and (ii) the second window at a second angle relative to the forward looking direction. Each of the first angle and the second angle is at least 95 degrees.

Abstract: The invention provides a p38 MAPK inhibitor of Formula I, or a pharmaceutically acceptable salt or solvate thereof: for use in the treatment or prevention of hypercytokinemia in a human patient; wherein R is C1-3alkyl, optionally substituted by one or more halo, NR1R2 or hydroxy, and R1and R2 are independently H, halo or C1-3alkyl, optionally substituted by one or more F. Also provided are compositions for use in the treatment or prevention of hypercytokinemia comprising the p38 MAPK inhibitor of Formula I; and methods for treating or preventing hypercytokinemia in a human patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a p38 MAPK inhibitor of Formula I. The invention also provides a p38 MAPK inhibitor and an antimicrobial agent, such as an antiviral agent, for use in the treatment or prevention of hypercytokinemia.

Abstract: A solidified melt extrudate comprising an active pharmaceutical ingredient in an amorphous form and a combination of at least two polymers.

Abstract: A process and system provides for atraumatic preparation of morselized Tissue Particles (TP)s, such as Full Thickness Skin Graft Particles (FTSGPs), cartilage particles and other organ tissue particles, in a liquid medium. The resultant tissue product may be a suspension of Tissue Particles in an aqueous solution and containing highly viable cells and may be rapidly prepared at bedside or in the operating room and conveniently delivered to a patient through a syringe or similar applicator. The morselized Tissues Particles may be used for surgical applications including wound healing, cosmetic surgery, and orthopedic cartilage repairs.

Abstract: A cloud-based platform for zero trust network access (ZTNA) services provides zero trust network access as a service for multiple customers in a multi-tenant architecture. In this context, the configuration for a new ZTNA application is validated with a service proxy in a sandbox or similar environment before release by the cloud-based platform for access through a public network. As a significant advantage, this approach mitigates inadvertent conflicts or instability in a service proxy that supports other applications and customers.

Abstract: A zero trust network access appliance deployed at a customer premises can support gateway and cloud modes. In a gateway mode, the appliance operates as a zero trust network access gateway, and provides zero trust network access to applications hosted at the customer premises, using a firewall at the customer premises for network security. In the cloud mode, the appliance initiates a secure connection with a remote, cloud computing platform that provides a front end for zero trust network access. A threat management facility for the customer provides a control plane for managing zero trust network access provided through the cloud computing platform.

Abstract: A cloud computing platform provides zero trust network access as a service to customers that maintain applications on-premises. In this context, the cloud computing platform may associate customers and/or applications with specific service proxies, and add an abstraction layer for network access that maps an alias domain for each customer and/or application to a network load balancer associated with the specific service proxies associated with the corresponding application(s). This approach advantageously simplifies the configuration of service proxies at the cloud computing platform by permitting dedicated relationships among network load balancers, specific service proxies, and specific applications, while concurrently reducing or avoiding the administrative burden on customers of updating network pointers when the clusters of service proxies are periodically reconfigured to adjust to varying user traffic.

Abstract: A cloud computing platform provides zero trust network access as a service to customers that maintain applications on-premises, and a zero trust network access appliance at the customer premises that couples the on-premises applications to the cloud computing platform. A customer may host multiple instances of the appliance in order to support scalable access, where each instance creates a separate secure tunnel to the cloud computing platform. In this context, when a new appliance authenticates a new secure tunnel, information such as a connector name, customer, and port for the tunnel may be shared on a control plane for the computing platform to facilitate programmatic load balancing within the cloud computing platform.

Abstract: Infrastructure for zero trust network access (ZTNA) is deployed as a cloud-based service remotely from a customer premises where user applications are hosted. By connecting an appliance on the customer premises to the cloud-based service through a secure tunnel or the like, an application hosted on the customer premises can then be accessed externally as a ZTNA application without the customer premises opening a firewall to public networks or otherwise exposing potential attack surfaces to the customer premises.

Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.

Abstract: Wellbore synthesis techniques are disclosed suitable for use in geothermal applications. Embodiments are provided where open hole drilled wellbores are sealed while drilling to form an impervious layer at the wellbore/formation interface. The techniques may be chemical, thermal, mechanical, biological and are fully intended to irreversibly damage the formation in terms of the permeability thereof. With the permeability negated, the wellbore may be used to create a closed loop surface to surface geothermal well operable in the absence of well casing for maximizing thermal transfer to a circulating working fluid. Formulations for the working and drilling fluids are disclosed.

Abstract: A patient interface system for delivery of respiratory therapy to a patient comprises: a nasal portion including a nasal chamber and a nasal sealing portion adapted to form a seal with the patients including an opening; an inlet conduit connected to the nasal portion to deliver the pressurized, breathable gas to the nasal chamber; and a nasal chamber coupling component adapted to form part of a releasable fluid coupling to enable the nasal portion to be fluidly coupled to a mouth portion to communicate a portion of the pressurized, breathable gas through the nasal chamber opening to the mouth portion.

Abstract: A humidification system can include a heater base, a humidification chamber, and a breathing circuit. A cartridge can be removably coupled to the heater base. The cartridge can include various sensors, probes, sensor wire connectors, heater wire connectors, and/or other features. The cartridge can include features configured to mate with corresponding features on the humidification chamber and the heater base. The cartridge includes a memory, such as an EEPROM, or other suitable storage device. When the cartridge is installed on the heater base, the memory is electrically connected to a processor and/or memory of the heater base. Various models of cartridges can be produced for use with different humidification chambers, breathing circuits, and/or therapies. A connector can be configured to couple an inspiratory conduit to an outlet port of the humidification chamber. The connector can provide a pneumatic connection to the outlet port and an electrical connection to the cartridge.

Abstract: A lubricating member for a hair removal device, in which the lubricating member includes a lubricating material, in which the lubricating material includes a polyglutamic acid (PGA) material. Also disclosed is a lubricating composition including: a matrix material and a lubricating material, in which the lubricating material includes a PGA material and the PGA includes at least 5% of the lubricating composition by weight. Also disclosed is a method of forming a corresponding lubricating member.

Abstract: Improved inspection techniques are described herein for checking for the presence of and identifying surface defects on a honeycomb body. The improved inspection utilizes measurement of travel of an outer surface of the honeycomb body to collect images of the outer surface. The images are combined into a composite image showing the outer surface of the honeycomb body. The composite image is analyzed to identify surface defects.

Abstract: The present invention relates to a method, apparatus, and system for communication with a user's family members using the DNA of the user without making the DNA profile public. According to a first aspect, there is provided a computer implemented method of locating one or more members of a familial network, comprising the steps of: generating one or more encryption keys derived from a first genomic sequence; encrypting a message using the or each encryption key to form an encrypted message; sending the encrypted message to one or more remote devices wherein decrypting the encrypted message at the one or more remote devices uses one or more encryption keys derived from a second genomic sequence; and receiving a confirmation regarding whether the decryption of the encrypted message was successful by any of the one or more remote devices.

Abstract: The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor) and/or anti-cancer therapy (e.g., chemotherapy such as a platinum doublet chemotherapy).

Abstract: Cervical collars, components thereof, and methods of using them overcome issues with conventional cervical collars.

Abstract: A system for cooling a hermetic motor includes a motor cooling refrigerant flow path configured to direct refrigerant from a condenser disposed along a refrigerant loop to a hermetic motor, and from the hermetic motor back to the refrigerant loop, and a housing of the hermetic motor disposed along the motor cooling refrigerant flow path and configured to receive the refrigerant from the condenser, wherein the housing of the hermetic motor comprises an annulus surrounding at least a portion of a stator of the hermetic motor, and wherein the annulus comprises a plurality of openings configured to direct refrigerant toward the stator and into a cavity of the housing of the hermetic motor.